AU2009240908B2 - Methods of administering antitumor agent comprising deoxycytidine derivative - Google Patents

Methods of administering antitumor agent comprising deoxycytidine derivative Download PDF

Info

Publication number
AU2009240908B2
AU2009240908B2 AU2009240908A AU2009240908A AU2009240908B2 AU 2009240908 B2 AU2009240908 B2 AU 2009240908B2 AU 2009240908 A AU2009240908 A AU 2009240908A AU 2009240908 A AU2009240908 A AU 2009240908A AU 2009240908 B2 AU2009240908 B2 AU 2009240908B2
Authority
AU
Australia
Prior art keywords
antitumor agent
patient
cyano
arabinofuranosyl
pyrimidinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009240908A
Other languages
English (en)
Other versions
AU2009240908A1 (en
Inventor
Kazuhito Arakawa
Hiroyuki Okabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delta Fly Pharma Inc
Original Assignee
Delta Fly Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Fly Pharma Inc filed Critical Delta Fly Pharma Inc
Publication of AU2009240908A1 publication Critical patent/AU2009240908A1/en
Assigned to SASAKI, TAKUMA, MATSUDA, AKIRA reassignment SASAKI, TAKUMA Request for Assignment Assignors: MATSUDA, AKIRA, SASAKI, TAKUMA, TAIHO PHARMACEUTICAL CO., LTD.
Assigned to DELTA-FLY PHARMA, INC. reassignment DELTA-FLY PHARMA, INC. Request for Assignment Assignors: MATSUDA, AKIRA, SASAKI, TAKUMA
Application granted granted Critical
Publication of AU2009240908B2 publication Critical patent/AU2009240908B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009240908A 2008-04-29 2009-04-28 Methods of administering antitumor agent comprising deoxycytidine derivative Active AU2009240908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/111,369 US7863255B2 (en) 2008-04-29 2008-04-29 Methods of administering antitumor agent comprising deoxycytidine derivative
US12/111,369 2008-04-29
PCT/JP2009/058725 WO2009133963A1 (en) 2008-04-29 2009-04-28 Methods of administering antitumor agent comprising deoxycytidine derivative

Publications (2)

Publication Number Publication Date
AU2009240908A1 AU2009240908A1 (en) 2009-11-05
AU2009240908B2 true AU2009240908B2 (en) 2013-10-03

Family

ID=41050984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009240908A Active AU2009240908B2 (en) 2008-04-29 2009-04-28 Methods of administering antitumor agent comprising deoxycytidine derivative

Country Status (8)

Country Link
US (1) US7863255B2 (https=)
EP (1) EP2268287B1 (https=)
JP (1) JP5570429B2 (https=)
AU (1) AU2009240908B2 (https=)
DK (1) DK2268287T3 (https=)
ES (1) ES2467968T3 (https=)
PL (1) PL2268287T3 (https=)
WO (1) WO2009133963A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
CN113727719A (zh) 2020-07-17 2021-11-30 德尔塔菲制药股份有限公司 血癌的新型治疗方法及新型治疗剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535231A1 (en) * 1990-06-15 1993-04-07 Sankyo Company Limited Pyrimidine nucleoside derivative
WO2005053699A1 (en) * 2003-12-04 2005-06-16 Cyclacel Limited Combination of a cdk inhibitor and cs-682 or a metabolite thereof
WO2007132228A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535231A1 (en) * 1990-06-15 1993-04-07 Sankyo Company Limited Pyrimidine nucleoside derivative
WO2005053699A1 (en) * 2003-12-04 2005-06-16 Cyclacel Limited Combination of a cdk inhibitor and cs-682 or a metabolite thereof
WO2007132228A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA, M., ET AL, "Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-B-Darabinofuranosylcytosine (CNDAC) against murine and human tumors". Cancer Letters, 1992, vol. 64, no. 1, pages 67-74 *

Also Published As

Publication number Publication date
JP5570429B2 (ja) 2014-08-13
EP2268287A1 (en) 2011-01-05
US20090270340A1 (en) 2009-10-29
ES2467968T3 (es) 2014-06-13
PL2268287T3 (pl) 2014-10-31
US7863255B2 (en) 2011-01-04
JP2011518761A (ja) 2011-06-30
DK2268287T3 (da) 2014-06-02
EP2268287B1 (en) 2014-05-21
WO2009133963A1 (en) 2009-11-05
AU2009240908A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
RU2587013C2 (ru) Комбинированная химиотерапия
EP1849470A1 (en) Anticancer drug containing alpha, alpha, alphatrifluorothymidine and thymidine phosphorylase inhibitor
AU2009240908B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
KR20210039414A (ko) 암의 치료를 위한 병용 요법
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SASAKI, TAKUMA; MATSUDA, AKIRA

Free format text: FORMER APPLICANT(S): MATSUDA, AKIRA; SASAKI, TAKUMA; TAIHO PHARMACEUTICAL CO., LTD.

PC1 Assignment before grant (sect. 113)

Owner name: DELTA-FLY PHARMA, INC.

Free format text: FORMER APPLICANT(S): SASAKI, TAKUMA; MATSUDA, AKIRA

FGA Letters patent sealed or granted (standard patent)